AU780206B2 - Antigenic proteins of shrimp white spot syndrome virus and uses thereof - Google Patents
Antigenic proteins of shrimp white spot syndrome virus and uses thereof Download PDFInfo
- Publication number
- AU780206B2 AU780206B2 AU20554/02A AU2055402A AU780206B2 AU 780206 B2 AU780206 B2 AU 780206B2 AU 20554/02 A AU20554/02 A AU 20554/02A AU 2055402 A AU2055402 A AU 2055402A AU 780206 B2 AU780206 B2 AU 780206B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- acid sequence
- wssv
- nucleic acid
- antigenic protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 117
- 102000004169 proteins and genes Human genes 0.000 title claims description 114
- 230000000890 antigenic effect Effects 0.000 title claims description 33
- 241000318927 Shrimp white spot syndrome virus Species 0.000 title claims description 12
- 229960005486 vaccine Drugs 0.000 claims description 47
- 150000007523 nucleic acids Chemical group 0.000 claims description 46
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- 239000012634 fragment Substances 0.000 claims description 37
- 241000238557 Decapoda Species 0.000 claims description 31
- 241000700605 Viruses Species 0.000 claims description 29
- 230000002163 immunogen Effects 0.000 claims description 25
- 241000238424 Crustacea Species 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 229940126580 vector vaccine Drugs 0.000 claims description 9
- 238000009007 Diagnostic Kit Methods 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 230000002238 attenuated effect Effects 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 description 93
- 241000696962 White spot syndrome virus Species 0.000 description 77
- 238000000034 method Methods 0.000 description 22
- 238000002255 vaccination Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000012790 confirmation Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000005090 green fluorescent protein Substances 0.000 description 8
- 241000238631 Hexapoda Species 0.000 description 7
- 241000238552 Penaeus monodon Species 0.000 description 7
- 241000701447 unidentified baculovirus Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 5
- 241000519995 Stachys sylvatica Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 101710094648 Coat protein Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000000514 hepatopancreas Anatomy 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HOSWPDPVFBCLSY-UHFFFAOYSA-N 2-azaniumyl-4-oxobutanoate Chemical compound OC(=O)C(N)CC=O HOSWPDPVFBCLSY-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- AIFHRTPABBBHKU-RCWTZXSCSA-N Arg-Thr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AIFHRTPABBBHKU-RCWTZXSCSA-N 0.000 description 1
- UZSQXCMNUPKLCC-FJXKBIBVSA-N Arg-Thr-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UZSQXCMNUPKLCC-FJXKBIBVSA-N 0.000 description 1
- 241000238582 Artemia Species 0.000 description 1
- 241000238569 Artemia sp. Species 0.000 description 1
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 1
- QRULNKJGYQQZMW-ZLUOBGJFSA-N Asp-Asn-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QRULNKJGYQQZMW-ZLUOBGJFSA-N 0.000 description 1
- BFOYULZBKYOKAN-OLHMAJIHSA-N Asp-Asp-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BFOYULZBKYOKAN-OLHMAJIHSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- ITGFVUYOLWBPQW-KKHAAJSZSA-N Asp-Thr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O ITGFVUYOLWBPQW-KKHAAJSZSA-N 0.000 description 1
- 241000238077 Astacidae Species 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- 241000238090 Astacus Species 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 241000701412 Baculoviridae Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000238094 Callinectes Species 0.000 description 1
- 241000238143 Cancridae Species 0.000 description 1
- 241000238155 Carcinus Species 0.000 description 1
- 241000781219 Coffea merguensis Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000382490 Gill-associated virus Species 0.000 description 1
- HJIFPJUEOGZWRI-GUBZILKMSA-N Glu-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N HJIFPJUEOGZWRI-GUBZILKMSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GAAHQHNCMIAYEX-UWVGGRQHSA-N Gly-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GAAHQHNCMIAYEX-UWVGGRQHSA-N 0.000 description 1
- 241000238072 Homarus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AGGIYSLVUKVOPT-HTFCKZLJSA-N Ile-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N AGGIYSLVUKVOPT-HTFCKZLJSA-N 0.000 description 1
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000238553 Litopenaeus vannamei Species 0.000 description 1
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 1
- 241000238559 Macrobrachium Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MYAPQOBHGWJZOM-UWVGGRQHSA-N Met-Gly-Leu Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C MYAPQOBHGWJZOM-UWVGGRQHSA-N 0.000 description 1
- ZYTPOUNUXRBYGW-YUMQZZPRSA-N Met-Met Chemical compound CSCC[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CCSC ZYTPOUNUXRBYGW-YUMQZZPRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000238069 Nephropidae Species 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000229375 Palaemon Species 0.000 description 1
- 241000238560 Palaemonidae Species 0.000 description 1
- 241000238035 Palinuridae Species 0.000 description 1
- 241000238038 Palinurus Species 0.000 description 1
- 241000238550 Penaeidae Species 0.000 description 1
- 240000007332 Podocarpus macrophyllus Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241001600157 Portunus Species 0.000 description 1
- AJBQTGZIZQXBLT-STQMWFEESA-N Pro-Phe-Gly Chemical compound C([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 AJBQTGZIZQXBLT-STQMWFEESA-N 0.000 description 1
- 241000238028 Procambarus Species 0.000 description 1
- 241000238030 Procambarus clarkii Species 0.000 description 1
- 241000700141 Rotifera Species 0.000 description 1
- VIIJCAQMJBHSJH-FXQIFTODSA-N Ser-Met-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O VIIJCAQMJBHSJH-FXQIFTODSA-N 0.000 description 1
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- GITNQBVCEQBDQC-KKUMJFAQSA-N Tyr-Lys-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O GITNQBVCEQBDQC-KKUMJFAQSA-N 0.000 description 1
- SVFRYKBZHUGKLP-QXEWZRGKSA-N Val-Met-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SVFRYKBZHUGKLP-QXEWZRGKSA-N 0.000 description 1
- RFZFBOQPPFCOKG-BZSNNMDCSA-N Val-Trp-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)O)N RFZFBOQPPFCOKG-BZSNNMDCSA-N 0.000 description 1
- 241000544286 Vibrio anguillarum Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000380111 Yellow head virus Species 0.000 description 1
- 101100023962 Zea mays VP15 gene Proteins 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 108010018691 arginyl-threonyl-arginine Proteins 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 108010021908 aspartyl-aspartyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 108010045397 lysyl-tyrosyl-lysine Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 108010085203 methionylmethionine Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/18011—Nimaviridae
- C12N2710/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/817—Viral vaccine for fish
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
WO 02/22664 PCT/EP01/10679 ANTIGENIC PROTEINS OF SHRIMP WHITE SPOT SYNDROME VIRUS AND USES
THEREOF
The present invention relates to antigenic proteins derived from White Spot Syndrome virus, the use of these proteins in vaccines, to vaccines on the basis of these proteins, to antibodies against the proteins, to the use of these antibodies in vaccines, nucleic acid sequences encoding them and use of said proteins in the manufacture of a vaccine for prophylaxis and/or treatment of White Spot Syndrome in crustaceans, to vector vaccines and to diagnostic kits.
White Spot Syndrome Virus (WSSV) is a major viral disease in shrimp world-wide. The virus has a wide host range among crustaceans (Flegel, 1997) and there is little genetic variation among isolates (Lo et al, 1999). Electron microscopy (EM) studies showed that' the virions are enveloped and have a rod to bullet shaped appearance of about 275 nm in length and 120 nm wide with a tail-like appendage at one end. Nucleocapsids, which have lost their envelope, have a crosshatched appearance and a size of about 300 nm x nm (Wongteerasupaya et al., 1995). This virion morphology, its nuclear localisation and its morphogenesis are reminiscent of baculoviruses in insects (Durand et al., 1997).
Originally, WSSV has been classified as an unassigned member of the Baculoviridae family (Francki et al., 1991) hence the virus has been referred to as Systemic Ectodermal Mesodermal Baculovirus (SEMBV) or White Spot Baculovirus (WSBV). At present WSSV is no longer accepted into this family (Murphy et al., 1995) due to lack of molecular information. The double stranded viral DNA has a size of well over 200kb as derived from restriction endonuclease analysis (Yang et al., 1997).
An outbreak of WSSV in cultured shrimp causes mass mortality among shrimp. The disease is characterised by white spots on the carapace, appendages and cuticle and reddish coloration of the hepatopancreas of the shrimp. The infected shrimps show signs of lethargy and a rapid reduction in food consumption and within 3 to 5 days these shrimps die. An outbreak of WSSV leads to heavy losses in the industry of cultured shrimp and as a consequence there is a strong need for vaccines that can protect against WSSV infections. The identification and characterisation of major WSSV I CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 2 proteins that can be used in such a vaccine would provide the means to develop such vaccines.
Two genes have been isolated and identified as vp19 and vp13, coding for the respective proteins VP13 (13 kDa) and VP19 (19 kDa) due to their molecular weight estimated from their mobility in Coomassie Brilliant Blue-stained SDS-PAGE gels. VP19 is an envelope protein, whereas VP13 is a nucleocapsid protein. The open reading frame of vp19 comprises 366 nucleotides as shown in SEQ ID NO1 together with the deduced amino acid sequence consisting of 121 amino acids (separately depicted as SEQ ID NO The open reading frame of the gene vp13 comprises at least the 186 nucleotides as depicted in SEQ ID NO 3. This ORF encodes a nudeocapsid protein VP13 comprising the amino acid sequence shown in SEQ ID N04. Two variants of protein VP13 were found, one having the amino acid sequence depicted in SEQ ID NO 4, and a longer variant having the amino acid sequence depicted in SEQ ID NO The present invention provides a means to produce recombinant vaccines to protect crustaceans against infection with WSSV. The envelope protein VP19 and the nucleocapsid protein VP13 of WSSV which have been identified and characterised were found to be suitable for use in the manufacture of a subunit vaccine to protect crustaceans against infections with WSSV. The cloning and characterisation of the nucleotide sequences of the present invention provides for the production of these proteins of WSSV using recombinant technology techniques. In this way, WSSV proteins can be obtained, which are substantially free from other WSSV proteins. The isolated WSSV proteins can be used to manufacture subunit vaccines to protect crustaceans against infection of WSSV.
The proteins of the present invention are especially useful in marker vaccines. Such vaccines may comprise e.g. only VP13 and/or 19.
Alternatively the nucleotide sequences encoding the proteins of the WSSV can be used to manufacture vector vaccines to protect crustaceans against the infection with WSSV.
The nucleotide sequences of the present invention can furthermore be used for diagnostic purposes, for instance to detect the presence of WSSV in the field.
Additionally, the WSSV proteins of the present invention can be used to produce WSSV specific antibodies. These antibodies can be used to produce WSSV vaccines for CONFIRMATION COPY passive immunization of crustaceans. The antibodies can also be used for diagnostic purposes such as the detection of WSSV in crustaceans or in the field.
Thus a first aspect of the invention provides an isolated antigenic protein of WSSV that is suitable for immunizing crustaceans against WSSV that has an amino acid sequence that is at least 70% homologous to the amino acid sequence as depicted in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5 and to immunogenic fragments of said protein.
In one embodiment the WSSV proteins have a sequence homology of at least preferably 90%, more preferably 95% homology to the amino acid sequence as depicted in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5 and to immunogenic fragments of such 0to proteins.
Even more preferred is a homology level of 98% or even 100%.
The level of protein homology can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTP", that can be found at www.ncbi.nlm.nih.gov/blast/bl2seqi/bl2.html.
S 15I A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS Microbial. Letters 174: 247-250 (1999). Matrix used: "blosum62". Parameters used are the default parameters: ~Open gap: 11. Extension gap: 1. Gap x_dropoff: According to a second aspect of the present invention there is provided a vaccine capable of protecting shrimp against WSSV infection wherein said vaccine comprises a protein or immunogenic fragment thereof according to the first aspect and a pharmaceutically acceptable carrier.
According to a third aspect of the present invention there is provided an isolated nucleic acid sequence encoding an antigenic protein according to the first aspect, or an S• 25 immunogenic fragment of said protein.
According to a fourth aspect of the present invention there is provided a vector vaccine for use in prophylaxis or treatment of White Spot Syndrome in crustaceans, wherein said vaccine comprises a live attenuated bacterium or live attenuated virus, said bacterium or virus comprising in its genome a heterologous nucleic acid sequence according to the third aspect.
According a fifth aspect of the present invention there is provided an antigenic protein according to the first aspect for use in a vaccine.
[R:\LIBVV\GDR] 10992.doc:THR -3a- According to a sixth aspect of the present invention there is provided the use of an antigenic protein according to the first aspect for the manufacture of a vaccine for combating WSSV infections.
According to a seventh aspect of the present invention there is provided antibodies raised against an antigenic protein according to the first aspect.
According to an eighth aspect of the present invention there is provided a vaccine comprising a pharmaceutically acceptable carrier and at least one antibody according to the seventh aspect.
According to a ninth aspect of the present invention there is provided a vaccine comprising a pharmaceutically acceptable carrier and a nucleic acid sequence according to the third aspect.
According to a tenth aspect of the present invention there is provided a diagnostic kit for detection of WSSV wherein said kit comprises a nucleic acid sequence that is at least 70% homologous to the nucleic acid sequence as depicted in SEQ ID NO: 1 or 3 or a o•O• is nucleotide sequence that is complementary to that nucleic acid sequence, or a fragment •thereof having a length of at least 12 nucleotides, an antigenic protein according to the first •ooo aspect or an immunogenic fragment thereof, or an antibody according to the seventh aspect.
•It will be understood that, for the particular proteins embraced herein, natural variations can exist between individual WSSV strains. These variations may be 20 demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence.
Amino acid substitutions which do not essentially alter biological and immunological activities, have been described, e.g. by Neurath et al in "The Proteins" Academic Press New 9.
York (1979). Amino acid replacements between related amino acids or replacements which S 25 have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, Atlas of protein sequence and structure, Nat. Biomed. Res.
[R:\LIBVV\GDR] I 0992.doc:THR WO 02/22664 PCTIEP01/10679 4 Found., Washington 1978, vol. 5, suppl. Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, AlaNal, Thr/Phe, Ala/Pro, Lys/Arg, Leu/lie, LeuNal and Ala/Glu. Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science,227, 1435-1441, 1985) and determining the functional similarity between homologous proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting proteins are not essentially affected in their antigenic or immunogenic properties.
This explains why WSSV proteins according to the invention, when isolated from different field isolates, may have homology levels of about 70%, while still representing the same protein with the same immunological characteristics.
Those variations in the amino acid sequence of a certain protein according to the invention that still provide a protein capable of inducing an immune response against infection with WSSV or at least against the clinical manifestations of the infection are considered as "not essentially affecting the antigenic or immunogenic properties of said protein". When a protein is used for e.g. vaccination purposes or for raising antibodies, it is however not necessary to use the whole protein. It is also possible to use a fragment of that protein that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that protein, a so-called immunogenic fragment An "immunogenic fragment" is understood to be a fragment of the full-length protein that still has retained its capability to induce an immune response in a vertebrate host, i.e.
comprises a B- or T-cell epitope. Antibodies raised in a vertebrate host are very suitable as passive means of vaccination in shrimps. At this moment, a variety of techniques is available to easily identify DNA fragments encoding antigenic fragments (determinants).
The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO 86/06487, US Patent NR. 4,833,092, Proc. Natl Acad. Sci. 81: 3998- 4002 (1984), J. Imm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 immunologically important regions of the protein. The method is used world-wide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes. Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific protein fragments as the immunologically important epitopes on the basis of their sequential and/or structural agreement with epitopes that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78: 38248-3828 (1981)), and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and US Patent 4,554,101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and US Patent application NTIS US 07/005,885). A condensed overview is found in: Shan Lu on common principles: Tibtech 9: 238-242 (1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vaccine 10: 3-7 (1992), Berzowsky for HIV-epitopes; The FASEB Journal 5:2412-2418 (1991).
Another embodiment of the invention relates to vaccines capable of protecting shrimp against WSSV infection, that comprise an antibody reactive with a protein or immunogenic fragment according to the invention as described above, together with a pharmaceutically acceptable carrier.
Still another embodiment of the invention relates to vaccines capable of protecting shrimp against WSSV infection, that comprise a protein or immunogenic fragment thereof according to the invention as described above together with a pharmaceutically acceptable carrier.
Still another embodiment of the invention relates to a nucleic acid sequence encoding an antigenic protein according to the invention, or an immunogenic fragment thereof.
More particularly this embodiment of the invention relates to a nucleic acid sequence encoding an antigenic protein or an immunogenic fragment thereof comprising an amino acid sequence as depicted in SEQ ID No.'s 2, 4, or CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 6 Preferably, the nucleic acid sequence has or comprises the sequence as depicted in SEQ ID NO 1 or 3. The respective nucleotide sequences start with the ATG codon encoding the first M residue of the deduced amino acid sequence up to the codon encoding the C-terminal amino acid residue. It must be understood that for the purpose of this invention nucleic acid sequences that have sequence homology with the sequences depicted in SEQ ID N01 or SEQ ID NO 3 are also within the scope of the invention. The sequence homology for the purpose of this invention is considered to be at least 70%, preferably 75%, more preferably 80%, even more preferably 85%. Highly preferred are nucleic acid sequences that have sequence homology with the sequences depicted in SEQ ID NO 1 or 3 of at least 90% more preferably Homologies of 98 or even 100% are even more preferred.
For the purpose of this invention sequence homology is determined by comparing the nucleotide sequence of interest with the corresponding part of the sequence depicted in SEQ ID NO 1 or 3. For the purpose of this invention the percentage sequence homology is defined as the percentage of identical nucleotides between the compared sequences.
The level of nucleotide homology can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTN" that can be found at www.ncbi.nlm.nih.gov/blast/bl2se/bl2.html.
A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS Microbiol. Letters 174: 247-250 (1999). Parameters used are the default parameters: Reward for a match: Penalty for a mismatch: Open gap: 5. Extension gap: 2.
Gap x_dropoff: Nucleic acid sequences having sequence homology according to the invention can easily be isolated with one of the sequences depicted in SEQ ID NO 1 or 3 or with fragments of this sequence from closely related WSSV strains using routine cloning and hybridisation techniques. For this purpose hybridisation is carried out under stringent, preferably highly stringent conditions. Stringent hybridisation conditions are understood to be washing'conditions of 1 x SSC, 0.1%SDS at a temperature of 65 0 C; highly stringent conditions refer to washing conditions in which the concentration SSC is being CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 7 lowered towards 0.3 x SSC. The specific information should not be so narrowly interpreted so as to require exclusion of erroneously identified bases. The specific sequences disclosed herein can be readily used to isolate homologous nucleotide sequences from other strains.
A nucleic acid sequence that has sequence homology with one of the sequences depicted in SEQ ID NO 1 or 3 encodes a protein having an amino acid sequence which comprises alterations compared to one of the amino acid sequences depicted in SEQ ID .No.'s 2, 4, or 5, whereby said alterations do not essentially affect the antigenic or immunogenic properties of said protein.
The WSSV proteins according to the invention can be obtained via standard biochemical isolation and purification methods or they can be prepared via general recombinant technology. The nucleotide sequences according to the invention are particularly suitable to be used for the recombinant production of WSSV proteins, substantially free from other WSSV proteins. The nucleotide sequences are incorporated into a suitable expression vector capable of expressing the proteins, transforming a suitable host cell with said expression vector and culturing the host cell in a suitable medium. The.
expressed proteins can be isolated and purified from the cells or the medium. Suitable expression vectors are, amongst others, plasmids, cosmids, viruses and YAC's (Yeast Artificial Chromosomes) which comprise the necessary control regions for replication and expression. The expression vector can be brought to expression on a host cell.
Suitable host cells are, for instance, bacteria, yeast cells, insect cells and mammalian cells. Such expression techniques are well known in the art (Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989; King and Possee, 1992).
In addition, the nucleic acid sequences according to the invention can be used to manufacture a vector vaccine to vaccinate crustaceans against WSSV infections. A vector vaccine is understood to be a vaccine in which a live, attenuated bacterium or virus has been modified so that it contains one or more heterologous nucleotide sequences inserted into its genetic material. These so called vector bacteria or viruses are capable of co-expressing the heterologous proteins encoded by the inserted SUBSTITUTE SHEET (RULE 26) WO 02/22664 PCT/EP01/10679 8 nucleotides. Thus in a fourth aspect the invention provides for a vector vaccine for use in prophylaxis or treatment of White Spot Syndrome in crustaceans comprising a live attenuated bacteria or virus and a pharmaceutical acceptable carrier, in which said bacteria or virus has been modified to comprise in its genetic material one or more of the nucleotide sequences of the present invention. Shrimp infected with such LRCs will produce an immunological response not only against the immunogens of the carrier, but also against the immunogenic parts of the protein(s) for which the genetic code is .additionally cloned into the LRC.
As an example of bacterial LRCs, bacteria such as Vibrio anguillarum known in the art can attractively be used. (Singer, J.T. et al., New Developments in Marine Biotechnology, p. 303-306, Eds. Le Gal and Halvorson, Plenum Press, New York, 1998).
Also, LRC viruses may be used as a way.of transporting the nucleic acid sequence into a target cell. Viruses suitable for this task are e.g. Yellow Head virus and Gill Associated virus, both belonging to the family coronaviridae.(see e.g. Spann, K.M. et al., Dis. Aquat, Org. 42: 221-225, (2000), and Cowley, J.A. et al., Dis. Aquat. Org. 36:153-157 (1999) for the virus, or Enjuanes, L. et al., p. 28-31 of the Proceedings of the ESW, Brescia, Italia, 27-30 August 2000 for live recombinant carrier corona viruses).
The technique of in vivo homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid sequence into the genome of a bacterium or virus of choice, capable of inducing expression of the inserted nucleic acid sequence according to the invention in the host animal.
An alternative and efficient way of vaccination is direct vaccination with DNA encoding the relevant antigen. Direct vaccination with DNA encoding proteins has been successful for many different proteins. (As reviewed in e.g. Donnelly et al., The Immunologist 2: 20-26 (1993)). This way of vaccination is attractive for the vaccination of shrimp against WSSV infection. Therefore, still another embodiment of the invention relate to vaccines comprising a pharmaceutically acceptable carrier and nucleic acid SUBSTITUTE SHEET (RULE 26) WO 02/22664 PCT/EP01/10679 9 sequences encoding a protein according to the invention or immunogenic fragments thereof, or DNA fragments, e.g. plasmids, that comprise such nucleic acid sequences.
Still another embodiment of the present invention relates to a protein according to the invention for use in a vaccine.
Again another embodiment of the invention relates to the use of a protein according to the invention for the manufacturing of a vaccine for combating WSSV infections.
A vaccine according to the invention can be used to protect crustaceans such as shrimps including but not limited to members from the Penaeidae family such as for example P.monodon, P.vannamei, P.chinensis, P.merguensis, or Metapeaeus spp.; prawns including but not limited to members from the Palaemonidae family such as for example Macrobrachium spp. or Palaemon spp.; lobsters including but not limited to members from the Palinuridae and Nephropidae family such as for example Calinectes spp., Palinurus spp., Panuliris spp. or Homarus spp.; crayfish including but not limited to members from the Astacidae family examples of which are Astacus spp., Procambarus spp., and Oronectes spp.; and crab including but not limited to members from the Cancridae and Portuidae family, examples of which are Cancer spp., Callinectes spp., Carcinus spp. and Portunus spp.
A vaccine according to the invention can be prepared according to techniques well known to the skilled practitioner and described for instance in Remington's Pharmaceutical Sciences, 18' edition (1990), eds. A.R. Gennaro et al., chapter 72, pp.
1389-1404, Philadelphia College of Pharmacy and Science.
Vaccines according to the invention comprise an effective amount of one or more proteins, vector bacteria or virus according to the invention, and a pharmaceutical acceptable carrier. The term "effective" as used herein is defined as the amount sufficient to induce a protective response in the crustaceans. The amount of vector or protein will depend on the type of vector or protein, the route of administration, the time of administration, the species to be vaccinated as well as age, general health, temperature and diet.
SUBSTITUTE SHEET (RULE 26) WO 02/22664 PCT/EP01/10679 In general, a dosage of 0.01 to 1000 pg protein per animal, preferably 0.5 to 500 pg, more preferably 1 to 100 pg protein per animal can be used. In case of viral vector vaccines in general a dosage of 10^3 to 10A8 pfu (plaque forming units) per animal can very efficiently be used. Bacterial vector vaccines can be given very efficiently in doses of 10A 3 to 10^8 bacteria.
For DNA vaccination, amounts of DNA between 0.1 and 10 pg DNA per animal are very usefull doses.
Pharmaceutically acceptable carriers that are suitable for use in a vaccine according to the invention are sterile and physiologically compatible such as for example sterile water, saline, aqueous buffers such as alkali metal phosphates PBS), alcohol's, polyols and the like. In addition a vaccine according to the invention may comprise other additives such as adjuvants, stabilisers, anti-oxidants, preservatives and others.
Suitable adjuvants include but are not limited to aluminium salts or gels, carbomers, non-ionic block copolymers, tocopherols, monophosphoryllipid A, muramyldipeptide, oil emulsions, glucans, cytokines, saponins such as Quil A, and the like. The amount of adjuvant added depends on the nature of the adjuvant itself.
Suitable stabilisers for use in a vaccine according to the invention include but are not limited to carbohydrates such as sorbitol, mannitol, starch, sucrose, dextrin, and glucose, proteins such as albumin or casein, and buffers like alkaline phosphates.
Suitable preservatives include amongst others thimerosal and merthiolate.
The vaccines according to the invention can be administered via injection, immersion, dipping, spray or aerosol, or per oral. Preferably the vaccine is administered to the crustaceans via immersion or per oral, especially in case of commercial aqua culture farms.
For oral administration the vaccine is preferably mixed with a suitable carrier for oral administration i.e. cellulose, food or a metabolisable substance such as alpha-cellulose or different oils of vegetable or animals origin. Particularly preferred food carriers for oral delivery of the vaccine according to the invention are live-feed organisms which are able to encapsulate the vaccine. A very suitable way of obtaining this is to feed e.g. insect cells in which a protein according to the invention has been expressed, to live-feed organisms. Suitable live-feed organisms include but are not limited to plankton-like non- SUBSTITUTE SHEET (RULE 26) WO 02/22664 PCT/EP01/10679 11 selective filter feeders preferably members of Rotifera, Artemia, and the like. Highly preferred is the brine shrimp Artemia sp.
The proteins according to the invention can be used for the production of antibodies, using the general techniques available to the practitioner in the field. Preferably the proteins are used to produce specific monoclonal antibodies. Antibodies according to the invention can be prepared according to standard techniques. Procedures for immunising animals, e.g. mice with proteins and procedures for selection of hybridomas producing protein-specific monoclonal antibodies are well known in the art (see for example Cligan et al. (eds), Current protocols in Immunology 1992; Kohler and Milstein, i Nature 256, pp. 495-497, 1975; Steenbakkers et al., Mol. Biol. Rep. 19, pp. 125-134, 1994). The obtained antibodies may be utilised in diagnostics to detect WSSV in the field or to detect the presence of WSSV in the crustaceans. The nudeotide sequences according to the invention are also suitable for use in diagnostics. Said sequences or fragments thereof can be used in for instance PCR technology to detect the presence of WSSV in the field, or in the crustaceans.
A diagnostic test for the detection of WSSV is e.g. based upon the reaction of DNA isolated from the animal to be tested, with specific probes or it is e.g. a PCR test based upon the coding sequences for the proteins according to the invention or based upon nucleic acid sequences that are complementary to those coding sequences. If nucleic acid molecules specific for the WSSV proteins according to the invention are present in the animal, these will e.g. specifically bind to specific PCR-primers and will subsequently become amplified in PCR-reaction. The PCR-reaction product can then easily be detected in DNA gel electrophoresis. PCR reactions are well-known in the art (see reference below). The nucleic acid molecules can most easily be isolated from the hepatopancreas of the animal to be tested. Standard PCR-textbooks give methods for determining the length of the primers for selective PCR-reactions with nucleic acid molecules specific for proteins according to the invention. Primers with a nucleotide sequence of at least 12 nudeotides are frequently used, but primers of more than more preferably 18 nucleotides are somewhat more selective. Especially primers with a CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 12 length of at least 20, preferably at least 30 nucleotides are very generally applicable.
PCR-techniques are extensively described in (Dieffenbach Dreksler, PCR primers, a laboratory manual. ISBN 0-87969-447-5 (1995)).
Nucleic acid molecules encoding a WSSV protein according to the invention or parts of those nucleic acid molecules having a length of at least 12, preferably 15, more preferably 18, even more preferably 20, 22, 25, 30, 35 or 40 nucleotides in that order of preference, wherein the nucleic acid molecules or parts hereof have at least 70 homology with the nucleic acid sequence as depicted in SEQ ID NO: 1 or 3 or a nucleic acid sequence that is complementary to nucleic acid sequence as depicted in SEQ ID NO: 1 or 3 are therefore also part of the invention. Such nucleic acid molecules can e.g.
be used as primers in PCR-reactions in order to enhance the amount of nucleic acid that encodes the proteins according to the invention. This allows the quick amplification of specific nucleotide sequences for use as a diagnostic tool for e.g. the detection of WSSV in tissue as indicated above.
Another nucleic acid-based test is based upon classical hybridisation with radioactively or colour labelled protein-specific cDNA-fragments. Both PCR-reactions and hybridisation reactions are well-known in the art and are i.a. described in Maniatis/Sambrook (Sambrook, J. et al. Molecular cloning: a laboratory manual. ISBN 0- 87969-309-6).
Thus, another embodiment of the invention relates to a diagnostic kit for the detection of WSSV wherein the test comprises a nucleic acid sequence that is at least 70 homologous to the nucleic acid sequence as depicted in SEQ ID NO: 1 or 3 or a nucleotide sequence that is complementary to that nucleic acid sequence, or a fragment thereof having a length of at least 12, preferably 15, more preferably 18 nudeotides.
A diagnostic test based upon the detection of antigenic material of WSSV proteins and therefore suitable for the detection of WSSV infection can e.g. also be a standard sandwich-ELISA test. In one example of such a test the walls of the wells of an ELISA plate are coated with antibodies directed against the protein according to the invention CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 13 or immunogenic fragments thereof. After incubation with the material to be tested, labelled anti-WSSV antibodies are added to the wells. A colour reaction then reveals the presence of antigenic material from WSSV.
Therefore, still another embodiment of the present invention relates to a diagnostic test for the detection of WSSV, characterised in that said test comprises antibodies against a protein or an immunogenic fragment thereof according to the invention.
Thus, in another aspect, the present invention provides for a diagnostic kit comprising one or more nucleotide sequences or antibodies according to the invention.
The antibodies raised against the proteins according to the invention can further be used to manufacture antibody vaccines for the passive immunisation of the crustaceans.
Thus, in a further aspect, the present invention provides for a vaccine for passive immunisation against WSSV wherein the vaccine comprises antibodies raised against a protein comprising an amino acid sequence as shown in SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 5. Such a vaccine can be prepared using standard techniques, as mentioned above. Preferably a vaccine for oral administration of the antibodies is prepared, in which the antibodies are mixed with an edible carrier such as fish food.
More preferably, the vaccine is prepared from antibodies prepared in chicken eggs (IgY antibodies).
Methods for large-scale production of antibodies according to the invention are also known in the art. Such methods rely on the cloning of (fragments of) the genetic information encoding the protein according to the invention in a filamentous phage for phage display. Such techniques are described i.a. at the "Antibody Engineering Page" under "filamentous phage display" at http://aximtl.imt.unimarburq.de/~rek/aepphaqe.html., and in review papers by Cortese, R. et al., (1994) in Trends Biotechn. 12: 262-267., by Clackson, T. Wells, J.A. (1994) in Trends Biotechn.
12: 173-183, by Marks, J.D. et al., (1992) in J. Biol. Chem. 267: 16007-16010, by Winter, G. et al., (1994) in Annu. Rev. Immunol. 12: 433-455, and by Little, M. et al., (1994) Biotechn. Adv. 12: 539-555. The phages are subsequently used to screen camelid expression libraries expressing camelid heavy chain antibodies. (Muyldermans, CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 14 S. and Lauwereys, Joum. Molec. Recogn. 12:131-140 (1999) and Ghahroudi, M.A.
et al., FEBS Letters 414: 512-526 (1997)). Cells from the library that express the desired antibodies can be replicated and subsequently be used for large scale expression of antibodies.
REFERENCES
Durand, Ughtner, D. Redman, R. and Bonami, J. R. (1997). Ultrastructure and morphogenesis of White Spot Syndrome Baculovirus (WSSV). Diseases Aquat. I Organisms 29, 205-211.
Flegel, T. W. (1997). Major viral diseases of the black tiger prawn (Penaeus monodon) in Thailand. World J. Microbiol. Biotechnol. 13, 433-442.
Francki, R. I. Fauquet, C. Knudson, D. and Brown, F. (1991). "Classification and Nomenclature of Viruses: Fifth Report of the International Committee on Taxonomy of Viruses'. Springer-Verlag, New York.
Lo, C. Hsu, H. Tsai, M. Ho, C. Peng, S. Kou, G. and Lightner, D. V.
(1999). Specific genomic fragment analysis of different geographical clinical samples of shrimp white spot syndrome virus. Diseases Aquat. Organisms..
Murphy, F. Fauquet, C. Bishop, D. H. Ghabrial, S. Jarvis, A. Martelli, G. Mayo, M. and Summers, M. D. (1995). "Classification and Nomenclature of Viruses: Sixth Report of the International Committee on Taxonomy of Viruses.". Virus Taxonomy Springer-Verlag, New York.
Sambrook, Fritsch, E. and Maniatis, T. (1989). "Molecular Cloning: A laboratory Manual." 2 ed. Cold Spring Harbor Laboratory, New York Wonteerasupaya, Vickers, J. Sriurairatana, Nash, G. Akarajamorn, A., Boonsaeng, Panyim, Tassanakajon, Withyachumnamkul, and Flegel, T.
W. (1995). A non-occluded, systemic baculovirus that occurs in cells of ectodermal and mesodermal origin and causes high mortality in the black tiger prawn Penaeus monodon. Diseases Aquat. Organisms 21, 69-77.
CONFIRMATION COPY WO 02/22664 WO 0222664PCTIEP01/10679 Yang, Wang, Chen, R. and Xu, X. (1997). A simple and efficient method for purification of prawn baculovirus; DNA. J. ViroL Meth. 67, 14.
CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 16
EXAMPLES
Example 1 Vaccination of Penaeus monodon with WSSV protein VP19.
Virus stock production A WSSV virus stock was produced in the crayfish Procambarus clarkii by intramuscular injection of purified WSSV. In order to determine the dilution resulting in 90-100% mortality in the black tiger shrimp P. monodon, an in vivo virus titration was performed using animals of approximately 1 gram in weight. The virus stock was diluted in steps from 1 x 105 to 5 x 1011 times in 330 mM NaCI and for each dilution 10 p C was injected intramuscularly into 10 shrimps. Shrimps that were injected with 330 mM NaCI, served as negative control for the infection. All shrimps serving as negative control (not shown) and those having received the 5 x 10" virus dilution survived, whereas mortality due to virus infection occurred in all groups with a lower virus dilution. Administration of virus dilutions of 1 x 10' and 1 x 107 resulted in almost 100% mortality in a period of 20 days.
A delay in mortality was observed when virus dilutions of 1 x 10' and 5 x 10 were used.
The 1 x 108 dilution resulted in 90% final mortality, but the time of mortality was delayed and spanned a period of 40 days. The experiment was repeated with the 1x107, the 1 x 108, and the 5x10 9 dilution yielding essentially the same results. The dilution of 1 x 108 was chosen as the virus dose for further experiments as this condition was expected to give the optimal response to the neutralisation in terms of mortality reduction.
Expression of WSSV proteins VP19 and VP13 in insect cells The VP19 and VP13 ORFs were expressed in insect cells using a baculovirus vector.
The Bac-to-Bac system (GIBCO BRL) was used to generate recombinant baculoviruses (AcMNPV) expressing the putative WSSV virion proteins VP19 and VP13 from the baculovirus polyhedrin promoter in insect cells. Recombinant viruses were generated expressing the Green Fluorescent Protein (GFP) from the p10 promoter and each of the WSSV proteins from the baculovirus polyhedrin promoter.
S/21 insect cells were infected with AcMNPV-WSSVvp19, and AcMNPV-WSSVvpl3 with a MOI of 5 and harvested at 72 h. post infection. Extracts of infected S/21 cells CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 17 were analysed in a 15% SDS-PAGE gel (Fig. Clear expression products can be observed for VP13 (Fig. 1, lane 5, and indicated here as VP15), which has the same electrophoretic mobility as its authentic counterpart in the WSSV virion (Fig. 1, lane A (less clear, but clearly visible) expression product could be observed for VP19 (Fig. 1, lane Therefore, a western analysis was carried out using a polyclonal antiserum raised against purified WSSV. This analysis showed that VP19 was expressed at the expected position (Fig. 1, lane and hence that the vp19 ORF encoded a WSSV virion protein.
Vaccination and challenge The experiment was set up according to the plan in table 1. Four experimental groups were used; two control groups, the negative and positive control, one group receiving VP19 and one group receiving GFP. In the GFP group, shrimps received the same mixture that was given to the VP19 group, with the exception of VP19.
Table 1. Group set-up of vaccination experiment Group Group name Vaccination Booster Challenge shrimp 1 Neg. control 330 mM NaCI 330 mM NaCI 330 mM NaCI 2 Pos. control 330 mM NaCI 330 mM NaCI WSSV 3 VP19 VP19 VP19 WSSV 4 GFP GFP GFP WSSV All groups were injected with 20 ld of their respective solutions. For the VP19 group and the GFP group a total amount of 15 pg of protein was administered for both the vaccination and booster. For dilution of the protein solutions, as well as the virus controls, a 330 mM NaCI solution was used. GFP is Green Fluorescent Protein. In the GFP group, shrimps received the same mixture that was given to the VP19 group, with the exception of VP19.
Five days after the vaccination, the shrimp were given a booster injection, two days later followed by injection of WSSV.
CONFIRMATION COPY WO 02/22664 PCT/EP01/10679 18 After the challenge, the shrimp were monitored for one week and dead shrimp were examined for the presence of WSSV by ELISA assays and electron microscopy.
None of the shrimp in group 1, the negative control, died of WSSV. Group 2 shrimps started dying of WSSV infection after one and a half-day and a mortality of 100% was reached after 5 days. The first animals in vaccination groups 3 died after one and a half day, but continued slower compared to group 2. Group 3 reached 100% mortality after six days post challenge and shows a clear delay in mortality compared to the positive control. This demonstrates that vaccination of P. monodon shrimp with the WSSV protein VP19 has a positive effect on the survival rate of the shrimps after challenge with
WSSV.
CONFIRMATION COPY WO 02/22664 WO 0222664PCT/EPOI/10679 19 Legend to the figures Figure 1. Lane 1 LMW Marker (Amersham pharmacia biotech), 2 SOS-PAGE gel of Purified WSSV, 3 SOS-PAGE gel of over-expressed VPI19, 4 Western blot with anti-WSSV of over-expressed VP1 9. 5 SOS-PAGE gel of over-expressed VPI 3 (indicated here as Figure 2. This figure shows the level of effect of vaccination on mortality of shrimps after challenge with WSSV: =VP19 vaccine, =negative control, positive control, G FP control.
CONFIRMATION COPY EDITORIAL NOTE APPLICATION NUMBER 20554/02 The following Sequence Listing pages 1 to 4 are part of the description. The claims pages follow on pages 20 to 21.
WO 02/22664 PCT/EPOI/10679 SEQUENCE LISTING <110> Akzo Nobel N.V.
<120> Antigenic proteins of Shrimp White SpotSyndrome virus and uses thereof <130> 200055Bep/pd <140> <141> <160> <170> Patentln Ver. 2.1 z2 10> <211> <2 12> <213> <220> <221> <222> <400> atg gc Met Al1 1 366
DNA
white spot syndrome virus
CDS
(366) 1 acc acg act aac act ctt cct ttc ggc agg acc gga gcc cag Thr Thr Thr Asn Thr Leu Pro Phe Gly Arg Thr Gly Ala Gin gcc gct ggc Ala A-la Gly atg gct cgc Met Ala Arg tct tac ace atg Ser Tyr Thr Met gat ctt gaa ggc Asp Leu Glu Gly tcc atg tct Ser Met Ser atg ggt ctc ttt Met Gly Leu Phe ate gtt get ate tea att ggt atc Ile Val Ala Ile Ser Ile Gly Ile 144 ctc gte Leu Val otg gec gte atg aat gta tgg atg gga cca aag aag gac agc Leu Ala Val Met Asn Val Trp Met Gly Pro Lys Lys Asp Ser 192 CONFIRMATION COPY WO 02/22664 WO 0222664PCTIEP01/10679 gat tot gac act gat Asp Ser Asp Thr Asp gac aco gtt gat Asp Thr Val Asp gac gao act gcc Asp Asp Thr Ala gat aac gat gat gag gao aaa tat aag aac agg aco agg gat Asp Asn Asp Asp Glu Asp Lys Tyr Lys Asn Arg Thr Arg Asp atg atg Met Met ctt ctg got Leu. Leu Ala ttt atg tot Phe Met Ser 115 <210> 2 <211> 121 <212> PRT <213> white too got ott ctg Ser Ala Leu Leu otc gtt tco goC Leu Val Ser Ala goc aco gtt Ala Thr Val 110 tao cc aag agg agg cag taa Tyr Pro Lys Arg Arg Gin 120 spot syndrome virus <400> 2 Met Ala Thr Thr Thr Asn Thr Leu Pro Phe Gly Arg Thr Giy Ala Gin Ala Ala Gly Met Ala Arg Ser Tyr Thr Met Asp Leu Glu Gly Ser Met Ser Met Gly Leu Phe Ile Val Ala Ile Ser Ile Giy Ile Leu. Val Leu Ala Val Met Asn Val Trp Met Gly Pro Lys Lys Asp Ser Asp Ser Asp Thr Asp Lys Asp Thr Val Asp Asp Asn Asp Asp Giu Asp Lys Tyr Lys Asn 90 Asp Asp Thr Ala Arg Thr Arg Asp Met Met CONFIRMATION COPY V t r WO 02/22664 WO 0222664PCTIEP01/10679 Leu Leu Ala Gly Ser Ala Leu 100 Leu Phe Leu. Val Ser Ala Ala Thr Val 105 110 Phe Met Ser Tyr Pro Lys Arg Arg Gin 115 120 <210> 3 <211> 186 <212> DNA <213> white spot syndrome virus <220> <221> CDS <222> <400> 3 atg gtt gcc cga agc tcc aag acc aaa Met Val Ala Arg Ser Ser Lys Trhr Lys 1 5 cgc cgt gga agc Arg Arg Gly Ser aag aag Lys Lys agg tcc acc Arg Ser Thr aag aag cgt Lys Lys Arg gct gga cgc atc tcc aag cgg agg ago Ala Gly Arg Ile Ser Lys Arg Arg Ser oca tca atg Pro Ser Met 96 gca gga aag aag Ala Gly Lys Lys too act gtc cgt cgc cgt tcc tca Ser Thr Val Arg Arg Arg Ser Ser 144 aag ago Lys Ser gga aag aag tot gga gcc cgc aag tca Gly Lys Lys Ser Gly Ala Arg Lys Ser 55 agg cgt taa Arg Arg <210> 4 <211> 61 <212> PRT <213> white spot syndrome virus 'r WO 02/22664 PCTIEPOI/10679 <400> 4 Met Val 1 Ala Arg Ser 5 Ser Lys Thr Lys Arg Arg Gly Ser Lys Lys Axg Ser Thr Lys Lys Arg Ala Gly Arg Ile Ser Lys Arg Arg Ser Pro Ser Met Ala Gly Lys Lys Ser Thr Val Arg Arg Arg Ser Ser Lys Ser Gly Lys Lys Ser Gly Ala Arg Lys Ser 55 Arg Arg <210> <211> <212> PRT <213> white spot syndrome virus <400> Met Thr 1 Lys Tyr Pro Glu Asn Lys Arg Leu Leu Ser Arg Asri Lys Glu Thr Leu Lys Val Ala Arg Ser Lys Thr Lys Ser Arg Arg Gly Arg Arg Ser Ser Lys Lys Arg Ser Thr Thr Ala Gly Arg Ile Ser Pro Ser Met Lys Lys Arg Ala Gly Lys Lys Ser Ser Thr Val Arg Arg Arg Ser Ser Lys Ser Gly Lys Lys Ser Gly Ar Ly Se g Arg Lys Ser Arg
Claims (15)
1. An isolated antigenic protein of WSSV suitable for immunising crustaceans against WSSV, wherein said antigenic protein has an amino acid sequence that is at least homologous to the amino acid sequence as depicted in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5 or an immunogenic fragment of said antigenic protein.
2. An antigenic protein according to claim 1, having a sequence homology of at least 80% to the amino acid sequence as depicted in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5 or an immunogenic fragment of said antigenic protein.
3. An antigenic protein according to claim 2 having a sequence homology of at least 90% to the amino acid sequence as depicted in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5, or an immunogenic fragment of said antigenic protein.
4. An antigenic protein according to claim 3 having a sequence homology of at least 95% to the amino acid sequence as depicted in SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 5, or an immunogenic fragment of said antigenic protein. Is 5. A vaccine capable of protecting shrimp against WSSV infection wherein said vaccine comprises a protein or immunogenic fragment thereof according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier. •.o
6. An isolated nucleic acid sequence encoding an antigenic protein according to Sany one of claims 1 to 4, or an immunogenic fragment of said protein.
7. A nucleic acid sequence according to claim 6, wherein said nucleic acid sequence comprises a sequence as depicted in SEQ ID NO: 1 or SEQ ID NO: 3.
8. A vector vaccine for use in prophylaxis or treatment of White Spot Syndrome in crustaceans, wherein said vaccine comprises a live attenuated bacterium or live attenuated virus, said bacterium or virus comprising in its genome a heterologous nucleic acid sequence according to claim 6 or 7.
9. An antigenic protein according to any one of claims 1 to 4 for use in a vaccine. Use of an antigenic protein according to any one of claims 1 to 4 for the manufacture of a vaccine for combating WSSV infections.
11. Antibodies raised against an antigenic protein according to any one of claims 1 to 4.
12. A vaccine comprising a pharmaceutically acceptable carrier and at least one antibody according to claim 11. [R:\LIBVV\GDR] 10992.doc:THR -21
13. A vaccine comprising a pharmaceutically acceptable carrier and a nucleic acid sequence according to claim 6 or 7.
14. A diagnostic kit for detection of WSSV wherein said kit comprises a nucleic acid sequence that is at least 70% homologous to the nucleic acid sequence as depicted in s SEQ ID NO: 1 or 3 or a nucleotide sequence that is complementary to that nucleic acid sequence, or a fragment thereof having a length of at least 12 nucleotides, an antigenic protein according to any one of claims 1 to 4 or an immunogenic fragment thereof, or an antibody according to claim 11. The diagnostic kit of claim 14 wherein the nucleic acid sequence fragment has o0 a length of at least 15 nucleotides.
16. The diagnostic kit of claim 15 wherein the nucleic acid sequence fragment has a length of at least 18 nucleotides.
17. An isolated antigenic protein of WSSV suitable for immunising crustaceans against WSSV substantially as hereinbefore described with reference to any one of the examples.
18. A vector vaccine for use in prophylaxis or treatment of White Spot Syndrome "4 *o in crustaceans substantially as hereinbefore described with reference to any one of the examples. Dated 17 January, 2005 4* *t Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON Akzo Nobel N.. S [R:\LIBVV\GDR 10992.doc:THR
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00203186 | 2000-09-15 | ||
| EP00203186 | 2000-09-15 | ||
| PCT/EP2001/010679 WO2002022664A2 (en) | 2000-09-15 | 2001-09-14 | Antigenic proteins of shrimp white spot syndrome virus and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2055402A AU2055402A (en) | 2002-03-26 |
| AU780206B2 true AU780206B2 (en) | 2005-03-10 |
Family
ID=8172024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU20554/02A Ceased AU780206B2 (en) | 2000-09-15 | 2001-09-14 | Antigenic proteins of shrimp white spot syndrome virus and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6908616B2 (en) |
| EP (1) | EP1366169A2 (en) |
| JP (1) | JP3780256B2 (en) |
| CN (2) | CN1193094C (en) |
| AU (1) | AU780206B2 (en) |
| CA (1) | CA2391407A1 (en) |
| EC (1) | ECSP024257A (en) |
| MX (1) | MXPA02004861A (en) |
| SG (1) | SG144692A1 (en) |
| WO (1) | WO2002022664A2 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004041005A (en) * | 2002-07-08 | 2004-02-12 | Gen Corp:Kk | White spotting disease-resistible composition |
| JP4731907B2 (en) * | 2002-09-16 | 2011-07-27 | アドバンスド バイオニュートリション コーポレーション | Protein and peptide expression for passive immunity |
| KR100489617B1 (en) * | 2002-09-24 | 2005-05-17 | 주식회사 단바이오텍 | Soluble antibody protein for prophylaxis and treatment of white spot syndrome virus infection, eggs containing thereof and method for producing thereof |
| US8633028B2 (en) | 2003-07-02 | 2014-01-21 | Musc Foundation For Research Development | dsRNA induced specific and non-specific immunity in crustaceans and other invertebrates and biodelivery vehicles for use therein |
| CN101023095B (en) * | 2004-07-09 | 2013-07-03 | 绿色生命实验室有限公司 | Genetic engineering protein P40 and application thereof |
| KR100782332B1 (en) * | 2006-01-23 | 2007-12-06 | 주식회사 바이오리더스 | Cell Surface Expression Vector for WSSV Antigen and Microorganism Transformed by the Same |
| CN1932520B (en) * | 2006-09-29 | 2012-03-21 | 武汉大学 | Test paper bar for detecting praw white spot syndrome virus and producing process thereof |
| CN101919873B (en) * | 2010-07-16 | 2011-05-04 | 韩健宝 | Nucleic acid medicament for resisting white spot syndrome viruses (WSSVs) and/or taura syndrome viruses (TSVs) |
| EP2633049B1 (en) | 2010-10-27 | 2018-10-10 | Harrisvaccines Inc | Methods and compositions to protect aquatic invertebrates from disease |
| US10004797B2 (en) | 2010-10-27 | 2018-06-26 | Harrisvaccines, Inc. | Method of rapidly producing improved vaccines for animals |
| US8822427B2 (en) | 2010-10-27 | 2014-09-02 | Harrisvaccines | Methods and compositions to protect aquatic invertebrates from disease |
| MY153741A (en) | 2010-11-10 | 2015-03-13 | Univ Malaya | A method for producing bio-active agent for the prevention of disease caused by white spot syndrome baculovirus complex and a bio-active agent derived thereof |
| MY161995A (en) * | 2010-11-10 | 2017-05-31 | Univ Malaya | Vaccine against white spot syndrome virus |
| CN102174518B (en) * | 2011-01-30 | 2012-12-19 | 中国农业科学院哈尔滨兽医研究所 | Main cis-acting element of shrimp white spot syndrome virus (WSSV) iel promoter and transcription factor combined with same and application |
| WO2014191445A1 (en) * | 2013-05-31 | 2014-12-04 | Intervet International B.V. | Scale drop disease (sdd) causative virus and derivatives thereof |
| EP3802592A4 (en) * | 2018-06-05 | 2022-06-15 | Novobind Livestock Therapeutics Inc. | Antibodies against aquaculture disease-causing agents and uses thereof |
| CN110013485B (en) * | 2019-03-07 | 2021-07-20 | 汕头大学 | Application of antisense nucleic acid AMO-miR-9875 in preparation of anti-white spot syndrome virus preparation |
| CN110438054A (en) * | 2019-07-26 | 2019-11-12 | 上海海洋大学 | Vp19 transgenic blue algae and its purposes in preparation prevention and treatment shrimp white spot syndrome virus drug |
| KR102330545B1 (en) * | 2019-11-18 | 2021-11-29 | (주)애드바이오텍 | Manufacturing method of immunoglobulin y for preventing shrimp mortality |
| CN112094853A (en) * | 2020-09-24 | 2020-12-18 | 扬州大学 | White spot syndrome virus VP28 gene, recombinant protein, polyclonal antibody, preparation method and application |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834589A (en) * | 1990-12-14 | 1998-11-10 | New York University | Chimeric viral receptor polypeptides |
| US5824535A (en) * | 1996-01-17 | 1998-10-20 | Kou; Guang-Hsiung | Identification, purification and detection of WSBV (Baculovirus associated with white spot syndrome) |
| US5840535A (en) * | 1997-06-02 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | DNA encoding a zinc ring protein |
| EP1206550B1 (en) * | 1999-08-03 | 2005-11-16 | Akzo Nobel N.V. | Proteins derived from white spot syndrome virus and uses thereof |
| CN1303942A (en) * | 1999-11-24 | 2001-07-18 | 国家海洋局第三海洋研究所 | Prawn white spot baculovirus genome DNA sequence and cDNA sequence |
-
2001
- 2001-09-14 EP EP01984643A patent/EP1366169A2/en not_active Withdrawn
- 2001-09-14 US US10/129,806 patent/US6908616B2/en not_active Expired - Fee Related
- 2001-09-14 WO PCT/EP2001/010679 patent/WO2002022664A2/en not_active Application Discontinuation
- 2001-09-14 CA CA002391407A patent/CA2391407A1/en not_active Abandoned
- 2001-09-14 MX MXPA02004861A patent/MXPA02004861A/en unknown
- 2001-09-14 AU AU20554/02A patent/AU780206B2/en not_active Ceased
- 2001-09-14 SG SG200304221-5A patent/SG144692A1/en unknown
- 2001-09-14 JP JP2002526914A patent/JP3780256B2/en not_active Expired - Lifetime
- 2001-09-14 CN CNB018029892A patent/CN1193094C/en not_active Expired - Fee Related
- 2001-09-14 CN CNA2004101046687A patent/CN1651458A/en active Pending
-
2002
- 2002-05-15 EC EC2002004257A patent/ECSP024257A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20040028700A1 (en) | 2004-02-12 |
| CA2391407A1 (en) | 2002-03-21 |
| US6908616B2 (en) | 2005-06-21 |
| CN1193094C (en) | 2005-03-16 |
| ECSP024257A (en) | 2002-08-01 |
| MXPA02004861A (en) | 2003-05-23 |
| WO2002022664A3 (en) | 2003-10-09 |
| CN1651458A (en) | 2005-08-10 |
| SG144692A1 (en) | 2008-08-28 |
| EP1366169A2 (en) | 2003-12-03 |
| JP2004508818A (en) | 2004-03-25 |
| AU2055402A (en) | 2002-03-26 |
| WO2002022664A2 (en) | 2002-03-21 |
| JP3780256B2 (en) | 2006-05-31 |
| CN1437654A (en) | 2003-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU780206B2 (en) | Antigenic proteins of shrimp white spot syndrome virus and uses thereof | |
| US7749506B2 (en) | Proteins derived from white spot syndrome virus and uses thereof | |
| DK179025B1 (en) | fish vaccine | |
| Shivappa et al. | Using a baculovirus insect/larvae | |
| CN100378124C (en) | Hsp70 from arthrobacter | |
| Binger et al. | Cloning and characterization of a surface antigen of Eimeria tenella merozoites and expression using a recombinant vaccinia virus | |
| JPH07196690A (en) | Vaccine for fowl coccidiosis | |
| EP1440086B1 (en) | Infectious salmon anaemia virus vaccine | |
| CA2624486A1 (en) | Novel sea lice vaccine | |
| WO2003000900A1 (en) | White spot syndrome virus vaccine | |
| AU2005212850B2 (en) | Ornithobacterium rhinotracheale subunit vaccines | |
| CA2442346C (en) | Nucleic acids encoding isav polypeptides |